Veru Inc. (NASDAQ:VERU) Short Interest Up 19.2% in January

Veru Inc. (NASDAQ:VERU) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 735,150 shares, an increase of 19.2% from the December 31st total of 616,770 shares. Based on an average trading volume of 127,880 shares, the days-to-cover ratio is currently 5.7 days. Approximately 5.4% of the shares of the stock are short sold. Approximately 5.4% of the shares of the stock are short sold. Based on an average trading volume of 127,880 shares, the days-to-cover ratio is currently 5.7 days.

Hedge Funds Weigh In On Veru

Several institutional investors have recently modified their holdings of VERU. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Veru in the 2nd quarter valued at approximately $36,000. Northwestern Mutual Wealth Management Co. bought a new stake in Veru in the third quarter valued at approximately $38,000. Allworth Financial LP bought a new stake in Veru in the second quarter valued at approximately $45,000. Cassaday & Co Wealth Management LLC acquired a new stake in Veru in the third quarter worth $47,000. Finally, XTX Topco Ltd bought a new position in shares of Veru during the second quarter worth $49,000. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on VERU shares. Oppenheimer reiterated an “outperform” rating on shares of Veru in a research report on Thursday, December 18th. Wall Street Zen cut shares of Veru from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Veru in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group assumed coverage on Veru in a research note on Thursday, December 18th. They issued a “buy” rating and a $25.00 target price for the company. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Veru Stock Performance

Shares of VERU stock opened at $2.57 on Tuesday. The firm’s 50 day moving average price is $2.43 and its two-hundred day moving average price is $3.25. Veru has a 52-week low of $2.10 and a 52-week high of $7.40. The stock has a market cap of $41.25 million, a PE ratio of -1.17 and a beta of -1.42.

Veru (NASDAQ:VERU) last issued its earnings results on Wednesday, December 17th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.18. During the same quarter in the prior year, the firm posted ($0.28) EPS. As a group, sell-side analysts predict that Veru will post -0.22 earnings per share for the current fiscal year.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.